These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34533119)

  • 21. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021.
    Marques AD; Sherrill-Mix S; Everett JK; Reddy S; Hokama P; Roche AM; Hwang Y; Glascock A; Whiteside SA; Graham-Wooten J; Khatib LA; Fitzgerald AS; Moustafa AM; Bianco C; Rajagopal S; Helton J; Deming R; Denu L; Ahmed A; Kitt E; Coffin SE; Newbern C; Mell JC; Planet PJ; Badjatia N; Richards B; Wang ZX; Cannuscio CC; Strelau KM; Jaskowiak-Barr A; Cressman L; Loughrey S; Ganguly A; Feldman MD; Collman RG; Rodino KG; Kelly BJ; Bushman FD
    mBio; 2021 Feb; 13(1):e0378821. PubMed ID: 35130727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant.
    Collier AY; Brown CM; McMahan KA; Yu J; Liu J; Jacob-Dolan C; Chandrashekar A; Tierney D; Ansel JL; Rowe M; Sellers D; Ahmad K; Aguayo R; Anioke T; Gardner S; Siamatu M; Bermudez-Rivera L; Hacker MR; Madoff LC; Barouch DH
    Sci Transl Med; 2022 Apr; 14(641):eabn6150. PubMed ID: 35258323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.
    Stærke NB; Reekie J; Nielsen H; Benfield T; Wiese L; Knudsen LS; Iversen MB; Iversen K; Fogh K; Bodilsen J; Juhl MR; Lindvig SO; Øvrehus A; Madsen LW; Klastrup V; Andersen SD; Juhl AK; Andreasen SR; Ostrowski SR; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Johansen IS; Lundgren J; Søgaard OS
    Nat Commun; 2022 Aug; 13(1):4466. PubMed ID: 35915081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Puhach O; Adea K; Hulo N; Sattonnet P; Genecand C; Iten A; Jacquérioz F; Kaiser L; Vetter P; Eckerle I; Meyer B
    Nat Med; 2022 Jul; 28(7):1491-1500. PubMed ID: 35395151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections.
    Siedner MJ; Boucau J; Gilbert RF; Uddin R; Luu J; Haneuse S; Vyas T; Reynolds Z; Iyer S; Chamberlin GC; Goldstein RH; North CM; Sacks CA; Regan J; Flynn JP; Choudhary MC; Vyas JM; Barczak AK; Lemieux JE; Li JZ
    JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34871181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active viral shedding in a vaccinated hospitalized patient infected with the delta variant (B.1.617.2) of SARS-CoV-2 and challenges of de-isolation.
    Alshukairi AN; Al-Omari A; Al-Tawfiq JA; El-Kafrawy SA; El-Daly MM; Hassan AM; Faizo AA; Alandijany TA; Dada A; Saeedi MF; Alhamlan FS; Al Hroub MK; Qushmaq I; Azhar EI
    J Infect Public Health; 2022 Jun; 15(6):628-630. PubMed ID: 35576779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients.
    Deng X; Evdokimova M; O'Brien A; Rowe CL; Clark NM; Harrington A; Reid GE; Uprichard SL; Baker SC
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
    Eyre DW; Futschik M; Tunkel S; Wei J; Cole-Hamilton J; Saquib R; Germanacos N; Dodgson AR; Klapper PE; Sudhanva M; Kenny C; Marks P; Blandford E; Hopkins S; Peto TEA; Fowler T
    Lancet Infect Dis; 2023 Aug; 23(8):922-932. PubMed ID: 37001541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
    Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals.
    Caserta LC; Martins M; Cronk B; Anderson R; Eldridge H; Gallow D; Kruppa F; Plocharczyk E; Diel DG
    Microbiol Spectr; 2022 Oct; 10(5):e0056322. PubMed ID: 36165775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals.
    Huai Luo C; Paul Morris C; Sachithanandham J; Amadi A; Gaston DC; Li M; Swanson NJ; Schwartz M; Klein EY; Pekosz A; Mostafa HH
    Clin Infect Dis; 2022 Aug; 75(1):e715-e725. PubMed ID: 34922338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
    Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
    BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why Does the SARS-CoV-2 Delta VOC Spread So Rapidly? Universal Conditions for the Rapid Spread of Respiratory Viruses, Minimum Viral Loads for Viral Aerosol Generation, Effects of Vaccination on Viral Aerosol Generation, and Viral Aerosol Clouds.
    Lee BU
    Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characterization of COVID-19 breakthrough infections, Philippines.
    Velasco JM; Vila V; Diones PC; Valderama MT; Mendez C; Turao-Agoncillo MMM; Chinnawirotpisan P; Manasatienkij W; Joonlasak K; Klungthong C; Jones A; Fernandez S; Navarro FC
    J Clin Virol; 2022 Jun; 150-151():105157. PubMed ID: 35413587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections.
    Zou J; Xie X; Liu M; Shi PY; Ren P
    mBio; 2022 Aug; 13(4):e0199622. PubMed ID: 35924850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
    Eick-Cost AA; Ying S; Wells N
    JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.